The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis

The Neuropsychological Effects of Extra-Virgin Olive Oil in People With Multiple Sclerosis

This is an open label feasibility trial to examine the effect of a complementary treatment with High Phenolic Extra Virgin Olive Oil (HPEVOO) on the cognitive and mental health of people with Multiple Sclerosis (MS), while receiving their standard medical treatment.

Study Overview

• Status: Active, not recruiting
• Conditions: Multiple Sclerosis
• Intervention / Treatment: Dietary supplement: High Phenolic Extra Virgin Olive Oil

• Study Type: Interventional
• Enrollment (Actual): 46
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Maria Loizou; Phone Number: 0035796651493; Email: loizou.g.maria@ucy.ac.cy

Study Locations

• Greece
  • Thessaloniki, Greece
    • Private medical office

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 63 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Clinical diagnosis of MS
• Must be between 18 to 65 years of age
• Both males and females are eligible for participation
• Must have at least five years of education
• Must be fluent in Greek language

Exclusion Criteria:

• Other neurological, psychiatric or chronic condition
• Enrollment in other trials/drug studies
• Experiencing side effects from previous treatments
• Inadequate visual and auditory acuity

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental Group; The Experimental Group will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment. EVOO will be consumed on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of supplementation.	Dietary supplement: High Phenolic Extra Virgin Olive Oil; Participants will be assigned in two groups: the Experimental Group (N= 20) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment, whereas the Control Group (N = 20) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.
No Intervention: Control Group; The Control Group will be continuing their standard medical treatment without additional supplementation. The neuropsychological assessment will be conducted at baseline, 6 months and 12 months +/- 7 days after their first assessment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symbol Digits Modalities Test (SDMT)	Change will be assessed in the SDMT score (0-100 range), over three time points. Higher score indicates better processing speed.	baseline, 6-months, 12-months
California Verbal Learning Test-Second Edition (CVLT-II)	Change will be assessed in the CVLT-II score (0-80 range), over three time points. Higher score indicates better auditory-verbal learning.	baseline, 6-months, 12-months
Brief Visuospatial Memory Test-Revised (BVMT-R)	Change will be assessed in the BVMT-R score (0-36 range), over three time points. Higher score indicates better visuospatial memory.	baseline, 6-months, 12-months
Wisconsin Card Sorting Test (WCST)	Change will be assessed in the WCST score over three time points. WCST examines attention, working memory and intellectual flexibility (0-64 score range). Higher scores represent worse performance.	baseline, 6-months, 12-months
Trail Making Test (TMT)	Change will be assessed in the TMT scores over three time points. TMT examines attention, intellectual flexibility and inhibition. Longer time to completion indicates worse performance.	baseline, 6-months, 12-months
The Vocabulary and Block Design from the Wechsler Adult Intelligence Scale (WAIS)	It will provide an estimated intelligence quotient (IQ) score	baseline
The Digit Span Test (DST) from WAIS	Change will be assessed in the DST score over three time points. DST examines working memory, 0-48 score range, higher scores indicate better working memory function.	baseline, 6-months, 12-months
Word List Generation (WLG) Test	Change will be assessed in the WLG score over three time points. WLG examines lexical fluency. The higher the number of words generated, the better is the performance.	baseline, 6-months, 12-months
Faux Pas Recognition (FPR) Test	Change will be assessed in the FPR score over three time points. FPR examines social cognition. Four different vignettes will be used for every assessment (0-20 score range). Higher scores indicate better performance.	baseline, 6-months, 12-months
Hospital Anxiety and Depression Scale (HADS)	Change will be assessed in the HADS scores over three time points. HADS examines anxiety, depression and psychological distress. Higher scores (0-42 range) indicate greater levels of anxiety and depression.	baseline, 6-months, 12-months
Health Status Questionnaire (SF-36)	Change will be assessed in SF-36 scores over three time points. SF-36 consists of eight scales (0-100 score range each) that examine physical and mental health-related quality of life. The lower the score the more disability.	baseline, 6-months, 12-months
Modified Fatigue Impact Scale (MFIS)	Change will be assessed in the MFIS score over three time points. MFIS examines how often fatigue interferes with daily activities. Higher scores (0-84 score range) indicate greater impact of fatigue on a person's activities.	baseline, 6-months, 12-months

Collaborators and Investigators

• Sponsor: University of Cyprus
• Collaborators: World Olive Center for Health; Ellis-Farm, Eliama Daily Value

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2022
• Primary Completion (Estimated): May 1, 2024
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: March 1, 2021
• First Submitted That Met QC Criteria: March 5, 2021
• First Posted (Actual): March 8, 2021

Study Record Updates

• Last Update Posted (Actual): November 2, 2023
• Last Update Submitted That Met QC Criteria: October 31, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Multiple Sclerosis; Sclerosis
• Other Study ID Numbers: NEEVOO.MS

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No